Vertex Pharmaceuticals Incorporated (VRTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 50 NORTHERN AVENUE
BOSTON, MA 02210
State of Incorp. MA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11,28910,56210,8959,8949,3258,393
Cash and cash equivalents10,1519,29010,5049,1728,7027,600
Short-term investments1,1381,272391722622793
Receivables1,5561,5481,4421,3851,3331,293
Inventory, net of allowances, customer advances and progress billings604535461388368339
Inventory604535461388368339
Prepaid expense   112   
Other current assets   74   
Other undisclosed current assets424321251604478336
Total current assets:13,87312,96613,23512,27111,50410,361
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization   316   
Operating lease, right-of-use asset324336347343318329
Property, plant and equipment   40   
Long-term investments and receivables1,3571,082    
Long-term investments1,3571,082    
Intangible assets, net (including goodwill)1,6921,6921,6921,6791,3891,402
Goodwill1,0881,0881,0881,0751,0021,002
Intangible assets, net (excluding goodwill)604604604604387400
Deferred income tax assets1,5381,3601,2471,1631,144946
Other noncurrent assets443428522133127111
Other undisclosed noncurrent assets1,1221,1127531,1191,1001,107
Total noncurrent assets:6,4766,0094,9164,4354,0793,895
TOTAL ASSETS:20,34918,97418,15116,70615,58214,256
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,9612,6492,4312,3912,3181,894
Accounts payable363323304127198174
Accrued liabilities2,5982,3262,1272,2642,1201,721
Other liabilities391377312218239286
Total current liabilities:3,3523,0262,7422,6092,5562,180
Noncurrent Liabilities
Long-term debt and lease obligation404418431825847873
Finance lease, liability404418431442482496
Liabilities, other than long-term debt1,1231,0981,065243245296
Other liabilities759727686116115117
Operating lease, liability364372380382365377
Business combination, contingent consideration, liability    127130179
Total noncurrent liabilities:1,5271,5161,4961,0681,0931,169
Total liabilities:4,8794,5424,2383,6773,6493,349
Equity
Equity, attributable to parent15,47014,43213,91313,03011,93410,907
Common stock333333
Additional paid in capital7,3697,2207,3877,2267,1006,930
Accumulated other comprehensive income (loss)(40)(13)1985811
Retained earnings8,1387,2236,5235,7044,7733,963
Total equity:15,47014,43213,91313,03011,93410,907
TOTAL LIABILITIES AND EQUITY:20,34918,97418,15116,70615,58214,256

Income Statement (P&L) ($ in millions)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues2,4932,3752,3032,3342,1962,098
Cost of revenue(309)(267)(283)(289)(262)(246)
Cost of goods and services sold(309)(267)(283)(289)(262)(246)
Gross profit:2,1852,1082,0192,0451,9341,852
Operating expenses(1,159)(1,331)(984)(921)(877)(818)
Other undisclosed operating income (loss) 12(2)3498
Operating income:1,0267791,0341,1271,1061,041
Nonoperating income (expense)1461245563(67)(71)
Investment income, nonoperating1451238646112
Other nonoperating income (expense)21(31)17(78)(73)
Other undisclosed loss from continuing operations before equity method investments, income taxes   (44)   
Income from continuing operations before equity method investments, income taxes:1,1739031,0451,1901,039970
Other undisclosed income (loss) from continuing operations before income taxes(11)(11)32(14)(15)(15)
Income from continuing operations before income taxes:1,1628921,0771,1761,024955
Income tax expense(246)(192)(258)(246)(214)(193)
Income from continuing operations:916700819931811762
Income before gain (loss) on sale of properties:931811762
Net income available to common stockholders, diluted:916700819931811762

Comprehensive Income ($ in millions)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income:916700819931811762
Other comprehensive income (loss)(4)1    
Comprehensive income:911701819931811762
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(22)(15)(97)4046(5)
Comprehensive income, net of tax, attributable to parent:889686722971857758

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: